This program centers on the validation of CD36 as a novel therapeutic target for dry AMD. As a scavenger receptor, CD36 is central to several pathophysiologies where oxidized lipids are implicated. Candidate molecules (azapeptides) have been validated in both cell-based and animal models of dry AMD and their immune-modulator effects on macrophage probed in depth. This program is a collaboration between Drs. Huy Ong, William Lubell and Sylvain Chemtob from the Université de Montréal and Maisonneuve Rosemont Hospital. This program was spun off into Mperia Therapeutics Inc; an AmorChem start-up company.